The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
The Effectiveness and Value of Esketamine for the Management of Treatment-Resistant Depression: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
Open accessAbstract
DISCLOSURES: Funding for this summary was contributed by the Laura and John Arnold Foundation, National Institute for Health Care Management, California Health Care Foundation, Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim Healthcare, and Kaiser Foundation Health Plan to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER's annual policy summit is supported by dues from Aetna, America's Health Insurance Plans, Anthem, AstraZeneca, Allergan, Alnylam, Biogen, Blue Shield of California, Cambia Health Services, CVS Caremark, Editas, Express Scripts, Genentech, GlaxoSmithKline, Harvard Pilgrim Health Care, Health Care Service Corporation, HealthPartners, HealthFirst, Johnson & Johnson (Janssen), Kaiser Permanente, LEO Pharma, Mallinkrodt Pharmaceuticals, Merck, Novartis, National Pharmaceutical Council, Premera, Prime Therapeutics, Regeneron, Sanofi, Spark Therapeutics, and United Healthcare. Agboola, Fazioli, and Pearson are employed by ICER. Touchette reports grants from ICER during the course of this work and personal fees from Monument Analytics, unrelated to this work. Atlas has nothing to disclose.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In 2019, ICER issued a recommendation that deemed Spravato to deliver a low value for money according to their value-assessment framework.
“In 2019, the Institute for Clinical and Economic Review (ICER) issued a recommendation that deemed SpravatoⓇ to deliver a “low value for money” according to their value-assessment framework”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [294]
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904 · cited 1×
“01).(9) However, a statistically significant difference was not observed between esketamine and placebo in TRANSFORM-1 and TRANSFORM-3.”
A Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996–2013
Mrazek, D. A., Hornberger, J. C., Altar, C. A., & Degtiar, I. (2014) · Psychiatric Services · doi:10.1176/appi.ps.201300059 · Cited by 580
Ochs-Ross, R., Daly, E. J., Zhang, Y., Lane, R., Lim, P., Morrison, R. L., Hough, D., Manji, H., Drevets, W. C., Sanacora, G., et al. (2020) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.10.008 · Cited by 481
Papadimitropoulou, K., Vossen, C., Karabis, A., Donatti, C., & Kubitz, N. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1277201 · Cited by 91 · cited 7×
“The Institute for Clinical and Economic Review (ICER) performed a systematic literature review and cost-effectiveness analysis to evaluate the health and economic outcomes of esketamine for the treatment of TRD. Complete details of ICER’s systematic literature search and protocol, as well as the methodology and model…”
Influential
Flagged first, then by citations
Research works printed but not linked: 5
- Lepine JP, 2011, Neuropsychiatr Dis Treat, 7, 3
- Ionescu DF, 2015, Dialogues Clin Neurosci, 17, 111, 10.31887/DCNS.2015.17.2/dionescu · DOI
- 10.1176/appi.ajp.2017.17020239 · DOI · Paper page
- Ochs-Ross R, 2019, Am J Geriatr Psychiatry, 27, S139, 10.1016/j.jagp.2019.01.047 · DOI
- Daly EJ, JAMA Psychiatry
Cited by
Sorted by citations
Psychedelics and Other Psychoplastogens for Treating Mental Illness.
Vargas, M. V., Meyer, R., Avanes, A. A., Rus, M., & Olson, D. E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.727117 · Cited by 166
Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis
Fountoulakis, K. N., Saitis, A., & Schatzberg, A. F. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240515 · Cited by 90
Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression
Vecera, C. M., C. Courtes, A., Jones, G., Soares, J. C., & Machado-Vieira, R. (2023) · Pharmaceuticals · doi:10.3390/ph16111572 · Cited by 48
“Independent groups conducting cost-effectiveness analyses have consistently determined that esketamine/Spravato exceeds standard cost-effectiveness thresholds and is currently too expensive for widespread or long-term use in the United States [107,108].”
Background
Metadata
- Authors
- Agboola, F., Atlas, S. J., Touchette, D. R., Fazioli, K., & Pearson, S. D.
- Affiliations
- Institute for Clinical and Economic Review (US)
- Massachusetts General Hospital (US)
- University of Illinois Chicago (US)
- Venue
- Journal of Managed Care & Specialty Pharmacy
- Publisher
- Academy of Managed Care Pharmacy
- Published
- 2020-01
- Volume
- 26
- Issue
- 1
- Pages
- 16-20
- ISSN
- 2376-0540 (ISSN-L)
- 2376-1032
- PMC
- PMC10391009
- OpenAlex
- W2998434856
- Cited by
- 24
- References
- 5
- Citations by year
- 2026: 2 · 2025: 3 · 2023: 6 · 2022: 4 · 2021: 5 · 2020: 4
- FWCI
- 2.01
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Managed Care & Specialty Pharmacy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- esketamine, treatment-resistant depression, antidepressant efficacy, economic evaluation, depression treatment
- MeSH terms
- Administration, Intranasal, Adolescent, Adult, Aerosols, Affect, Aged, Antidepressive Agents, Cost-Benefit Analysis, Female, Humans, Ketamine, Male, Middle Aged, Policy Making, Randomized Controlled Trials as Topic, Drug Costs, Treatment Outcome, Evidence-Based Medicine, Young Adult, Comparative Effectiveness Research, Patient Safety, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
